Gan & Lee Pharma's H1 Profit Rises 1%, Revenue Climbs 8%

Gan & Lee Pharmaceuticals H1 Net Profit up 1.01% Y/Y

Gan & Lee Pharmaceuticals Subsidiary Secures China Clinical Trial Nod for Weight Loss Drug

Executive Team Sells Shares at Gan & Lee Pharmaceuticals Amid Concerns Over Earnings Quality and Growth Ceiling

Pharmaceutical Rally Continues: Gan&Lee Pharmaceuticals Hits Limit-Up, Beone Medicines Logs 6-Day Winning Streak; Huabao Funds' HK Medical and Innovation Drug ETFs Rise for Third Consecutive Session

Gan & Lee Pharmaceuticals Grants Menarini Licensing Rights to Develop Diabetes Drug in Europe; Shares Jump 10%

Gan\u0026Lee Pharmaceuticals Signs Licensing Agreement with Menarini for Bofang Liraglutide Project

Gan & Lee Pharmaceuticals Gets China Nod for Breast Cancer Drug Trial

Gan & Lee Pharmaceuticals Secures Honduras Approval for Diabetes Drug; Shares Up 6%

Gan&Lee Pharmaceuticals Secures Honduran Regulatory Approval for Its Insulin Glargine Prefilled Pen

Gan & Lee Pharmaceuticals Gets Honduras Approval for Insulin Jab

Gan & Lee Pharmaceuticals Secures Registration Approval for Insulin Glargine Injection in Honduras

Gan & Lee Pharmaceuticals Seizes a Niche Opportunity in the Insulin Market

Gan & Lee Pharmaceuticals Secures UAE Drug Registration for Insulin Glargine Pre-filled Pen

Gan & Lee Pharmaceuticals - Once-Weekly Insulin Ludefen Shows Favorable Safety Profile With No Severe Hypoglycemia

Gan & Lee Pharmaceuticals - Insulin Ludefen (Gzr4) Meets Primary Endpoint in Phase Iii Trial in China

Gan & Lee Pharmaceuticals Unveils Restricted Stock Incentive Plan for 2026

Gan & Lee Pharmaceuticals Subsidiary Secures ANVISA Sterile Preparation GMP Certification in Brazil

Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Lispro Injection

Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe